Class actions filed against Stellantis, Immutep and Calix
U.S. law firm Bronstein, Gewirtz & Grossman LLC filed 6 month 7 day separate class actions against Stellantis, Immutep and Calix. The complaints allege false and misleading statements and the concealment of material information.
Bronstein, Gewirtz & Grossman LLC filed 6 month 7 day three class actions in court. The plaintiffs allege that statements by Stellantis, Immutep and Calix caused losses to investors. Each lawsuit covers investors who purchased the securities.
The Stellantis lawsuit alleges that the company made materially false or misleading statements regarding its profit growth outlook, electrification strategy and market position. The complaint states that Stellantis was not prepared to achieve its targets and would need substantial costs and provisions to reorganize its strategy. In particular, it points to a lack of preparedness related to battery electric vehicles. The lawsuit covers investors who purchased Stellantis securities between 2025 year 2 month 26 day and 2026 year 2 month 5 day.
The Immutep lawsuit alleges that the company misrepresented the progress and prospects of the TACTI-004 clinical trial. The plaintiffs allege that the company concealed negative clinical data and overstated the trial's operational progress and efficacy prospects. The lawsuit covers investors who purchased Immutep securities between 2025 year 3 month 24 day and 2026 year 3 month 12 day. The deadline for appointing lead plaintiffs is 2026 year 7 month 6 day.
The Calix lawsuit 1alleges that the company failed to disclose that quarterly margins benefited from advance purchases of high-end memory components. The complaint states that margins were under pressure due to reduced supply and rising component costs. The lawsuit concerns investors who purchased Calix securities between 2026year 1month 28and 2026year 4month 21day. The deadline for lead plaintiff applications is 2026year 7month 27day.
In all three cases, the plaintiffs allege that statements and disclosures by company management affected investors’ reasonable judgment. Each lawsuit allows investors who purchased during the relevant period to participate. Subsequent proceedings will involve court hearings and document exchanges.
Investors who purchased securities during the relevant period, or who are uncertain whether they purchased them, need to check the litigation notices and the deadline for lead plaintiff applications. The deadline for lead plaintiff applications in each lawsuit is the date specified earlier in the article.
Sources: GlobeNewswire Inc.
Bullstory synthesized this report from the linked sources. AI may have assisted the writing process. Check the original reports for factual confirmation.